On the last day of 2024, Lexington’s Valo Health Inc. also shared that its Phase 2 trial of OPL-0401 in patients with dia­bet­ic retinopa­thy did not meet its pri­ma­ry or sec­ondary end ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

With the expanded agreement, Novo will collaborate with Valo to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases. BY THE NUMBERS Under the ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

TARA Biosystems, a biotech startup that’s built a mechanism to generate human tissues outside of the body for drug development testing for cardiovascular therapeutics, has been acquired by Valo Health ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Novo Nordisk NOVO.B-1.86%decrease; red down pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Escape from Valo, the first middle grade novel in Phase III of The High Republic, adds fascinating new lore to lightsabers and how their colors can be temporarily changed. Warning: This article ...

(Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using ...